KR101240182B1 - 섬유근육통 증후군의 치료를 위한 아세틸 엘 카르니틴의용도 - Google Patents

섬유근육통 증후군의 치료를 위한 아세틸 엘 카르니틴의용도 Download PDF

Info

Publication number
KR101240182B1
KR101240182B1 KR1020077015272A KR20077015272A KR101240182B1 KR 101240182 B1 KR101240182 B1 KR 101240182B1 KR 1020077015272 A KR1020077015272 A KR 1020077015272A KR 20077015272 A KR20077015272 A KR 20077015272A KR 101240182 B1 KR101240182 B1 KR 101240182B1
Authority
KR
South Korea
Prior art keywords
acid
carnitine
acetyl
treatment
tartrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077015272A
Other languages
English (en)
Korean (ko)
Other versions
KR20070091317A (ko
Inventor
알레아르도 코베레치
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20070091317A publication Critical patent/KR20070091317A/ko
Application granted granted Critical
Publication of KR101240182B1 publication Critical patent/KR101240182B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
KR1020077015272A 2004-12-13 2005-11-10 섬유근육통 증후군의 치료를 위한 아세틸 엘 카르니틴의용도 Expired - Fee Related KR101240182B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000606A ITRM20040606A1 (it) 2004-12-13 2004-12-13 Uso della acetil l-carnitina per il trattamento della sindrome fibromialgica.
ITRM2004A000606 2004-12-13
PCT/EP2005/012054 WO2006063639A1 (en) 2004-12-13 2005-11-10 Use of acetyl l-carnitine for the treatment of fibromyalgic syndrome

Publications (2)

Publication Number Publication Date
KR20070091317A KR20070091317A (ko) 2007-09-10
KR101240182B1 true KR101240182B1 (ko) 2013-03-07

Family

ID=35708966

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077015272A Expired - Fee Related KR101240182B1 (ko) 2004-12-13 2005-11-10 섬유근육통 증후군의 치료를 위한 아세틸 엘 카르니틴의용도

Country Status (16)

Country Link
US (1) US8013016B2 (enExample)
EP (1) EP1824472B1 (enExample)
JP (1) JP5057990B2 (enExample)
KR (1) KR101240182B1 (enExample)
AT (1) ATE419847T1 (enExample)
CA (1) CA2585560C (enExample)
CY (1) CY1110576T1 (enExample)
DE (1) DE602005012317D1 (enExample)
DK (1) DK1824472T3 (enExample)
ES (1) ES2320788T3 (enExample)
IT (1) ITRM20040606A1 (enExample)
MX (1) MX2007006954A (enExample)
PL (1) PL1824472T3 (enExample)
PT (1) PT1824472E (enExample)
SI (1) SI1824472T1 (enExample)
WO (1) WO2006063639A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2840363A1 (en) * 2011-06-24 2012-12-27 K-Pax Pharmaceuticals, Inc. Compositions comprising a central nervous system stimulant and select micronutrients useful in the treatment of chronic fatigue
ES2962933T3 (es) 2020-12-14 2024-03-21 Ims Gear Se & Co Kgaa Procedimiento para la corrección de una señal de medición dependiente del tiempo de una unidad de motor-engranaje, así como procedimiento para detectar desgaste y/o un deterioro de la misma mediante este procedimiento de corrección

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096409A1 (en) 2001-05-29 2002-12-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain
US20040198837A1 (en) 1999-03-19 2004-10-07 Mendel Carl M. Treatment of neuropathic pain or fibromyalgia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1150396B (it) * 1982-12-09 1986-12-10 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico di miopa tie e distrofie muscolari
EP0681839A3 (en) * 1994-05-12 1997-11-12 Hirohiko Kuratsune A pharmaceutical preparation comprising an acylcarnitine
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US5935949A (en) * 1998-03-20 1999-08-10 Trustees Of Dartmouth College Use of androgen therapy in fibromyalgia and chronic fatigue syndrome
KR101027570B1 (ko) * 2002-05-03 2011-04-06 이스라엘 인스티튜트 포 바이올로지컬 리서치 중추 및 말초 신경계 장애의 치료를 위한 방법 및 조성물, 및 그에 유용한 신규 화합물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198837A1 (en) 1999-03-19 2004-10-07 Mendel Carl M. Treatment of neuropathic pain or fibromyalgia
WO2002096409A1 (en) 2001-05-29 2002-12-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain

Also Published As

Publication number Publication date
EP1824472B1 (en) 2009-01-07
ITRM20040606A1 (it) 2005-03-13
JP5057990B2 (ja) 2012-10-24
ATE419847T1 (de) 2009-01-15
US20090076146A1 (en) 2009-03-19
KR20070091317A (ko) 2007-09-10
CY1110576T1 (el) 2015-04-29
CA2585560C (en) 2013-01-08
PL1824472T3 (pl) 2009-05-29
SI1824472T1 (sl) 2009-04-30
ES2320788T3 (es) 2009-05-28
MX2007006954A (es) 2007-08-02
EP1824472A1 (en) 2007-08-29
CA2585560A1 (en) 2006-06-22
WO2006063639A1 (en) 2006-06-22
DK1824472T3 (da) 2009-03-30
JP2008534433A (ja) 2008-08-28
PT1824472E (pt) 2009-03-31
DE602005012317D1 (de) 2009-02-26
US8013016B2 (en) 2011-09-06

Similar Documents

Publication Publication Date Title
PT1463528E (pt) Inibidores selectivos da recaptação da serotonina e da norepinefrina para tratamento de síndrome de fibromialgia, síndrome da fadiga crónica e dor
US20200323823A1 (en) Methods for the treatment of depression
US20180051017A1 (en) Agent for treatment of schizophrenia
Rollinson et al. Postanoxic action myoclonus (Lance-Adams syndrome) responding to valproate
TWI250872B (en) Carbamate compounds for use in preventing or treating bipolar disorder
JP4276779B2 (ja) 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用
EP3400940B1 (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium
KR101240182B1 (ko) 섬유근육통 증후군의 치료를 위한 아세틸 엘 카르니틴의용도
EP1397128B1 (de) Kappa-opiatagonist für die behandlung der reizblase
EP1569635B1 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
WO2015046377A1 (ja) 膀胱・尿道協調不全改善剤
KR20200121819A (ko) 하지 불안 증후군을 치료하기 위한 치료제
MXPA06006685A (es) Uso de gaboxadol para tratar el insomnio.
US7776913B2 (en) Carnitines for treating or preventing disorders caused by andropause
KR101176347B1 (ko) 당뇨병 환자의 신경병 통증 치료용 약제의 제조를 위한아세틸 엘 카르니틴의 용도
TW202508584A (zh) 癌性疼痛預防或治療用組成物
TW202535357A (zh) 治療更年期及近更年期之方法
KR20250122413A (ko) 인지 기능을 개선시키는 약물을 제조하기 위한 조성물의 용도
TW202216145A (zh) 伴隨代謝異常之疾病或症候群中的肌力低下症狀之改善劑或預防劑
HK40000275B (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium
JPH08119858A (ja) 自閉症治療剤
HK1064036B (en) Kapp-opiate agonists for the treatment of bladder dieseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160301

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160301